SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from HEMOSENSE INC (CIK 0001127393) — Jun 27, 2005

HEMOSENSE INC (CIK 0001127393)
Date: June 27, 2005 · CIK: 0001127393 · Accession: 0001193125-05-132303

AI Filing Summary & Sentiment

File numbers found in text: 333-123705

Date
June 27, 2005
Author
LAZARD CAPITAL MARKETS LLC
Form
CORRESP
Company
HEMOSENSE INC (CIK 0001127393)

Letter

Via EDGAR Transmission and Facsimile Securities and Exchange Commission Division of Corporation Finance Fax: (202) 772-9218 Attention: Mary Beth Breslin Re: HemoSense, Inc. (File No. 333-123705) Acceleration Request

Dear Ms. Breslin:

On behalf of HemoSense, Inc. (the “Company”), we hereby respectfully request that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the Company’s Registration Statement on Form S-1 effective on June 28, 2005 at 10:00 a.m. E.D.T. or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the Commission. The Company hereby authorizes David J. Saul or David B. Crawford of Wilson Sonsini Goodrich & Rosati, P.C., counsel to the Company, to make such request on our behalf.

Please direct any questions regarding this filing to David J. Saul at (650) 320-4872.

Sincerely,

/s/ James D. Merselis

James D. Merselis

President and Chief Executive Officer

cc: David J. Saul

David W. Pollak

LAZARD CAPITAL MARKETS LLC

30 ROCKEFELLER PLAZA

NEW YORK, NEW YORK 10020

June 27, 2005

Via EDGAR Transmission and Facsimile

Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 6010

100 F Street, NE

Washington, DC 20549

Attention: Mary Beth Breslin

Re: HemoSense, Inc.

Registration Statement on Form S-1 (No. 333-123705)

Dear Ms. Breslin:

The undersigned, as managing underwriter for the public offering of the common stock of HemoSense, Inc., a Delaware corporation (the “Company”), hereby joins in the Company’s request that the effectiveness of the above-referenced Registration Statement on Form S-1 be accelerated so that said Registration Statement will become effective at 10:00 a.m., Washington, D.C. time, on June 28, 2005, or as soon thereafter as possible.

The number of preliminary prospectuses dated May 31, 2005 which have been distributed is as follows:

To Whom Delivered

No. of Copies

Underwriters

2,000

Individuals

Others

Total

3,150

Very truly yours,
LAZARD CAPITAL MARKETS LLC

Show Raw Text
CORRESP
1
filename1.htm

Acceleration Request

 HEMOSENSE, INC.

 651 RIVER OAKS PARKWAY

 SAN JOSE, CA 95134

 June 27, 2005

 Via EDGAR Transmission and Facsimile

 Securities and Exchange Commission

 Division of Corporation Finance

 Mail Stop 6010

 100 F Street, NE

 Washington, DC 20549

 Fax: (202) 772-9218

 Attention: Mary Beth Breslin

Re:
HemoSense, Inc. (File No. 333-123705)

 Acceleration Request

 Dear Ms. Breslin:

 On behalf of HemoSense, Inc. (the “Company”), we hereby
respectfully request that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the Company’s Registration Statement on Form S-1 effective on June 28, 2005 at 10:00 a.m. E.D.T. or as soon thereafter
as practicable, or at such later time as the Company may request by telephone to the Commission. The Company hereby authorizes David J. Saul or David B. Crawford of Wilson Sonsini Goodrich & Rosati, P.C., counsel to the Company, to make such
request on our behalf.

 Please direct any questions regarding
this filing to David J. Saul at (650) 320-4872.

Sincerely,

 /s/ James D. Merselis

James D. Merselis

President and Chief Executive Officer

cc:
David J. Saul

 David W. Pollak

 LAZARD CAPITAL MARKETS LLC

 30 ROCKEFELLER PLAZA

 NEW YORK, NEW YORK 10020

 June 27, 2005

 Via EDGAR Transmission and Facsimile

 Securities and Exchange Commission

 Division of Corporation Finance

 Mail Stop 6010

 100 F Street, NE

 Washington, DC 20549

 Attention: Mary Beth Breslin

Re:
HemoSense, Inc.

 Registration Statement on Form
S-1 (No. 333-123705)

 Dear Ms. Breslin:

 The undersigned, as managing underwriter for the public offering of the
common stock of HemoSense, Inc., a Delaware corporation (the “Company”), hereby joins in the Company’s request that the effectiveness of the above-referenced Registration Statement on Form S-1 be accelerated so that said Registration
Statement will become effective at 10:00 a.m., Washington, D.C. time, on June 28, 2005, or as soon thereafter as possible.

 The number of preliminary prospectuses dated May 31, 2005 which have been distributed is as follows:

 To Whom Delivered

No. of Copies

 Underwriters

2,000

 Individuals

700

 Others

450

 Total

3,150

 Very truly yours,

 LAZARD CAPITAL MARKETS LLC

 By:

 /s/ David G. McMillan, Jr.

 Name:

David G. McMillan, Jr.

 Title:

 Managing Director of Capital Markets,

 Head of Debt
& Equity